Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation

Group 1 - Polen Capital Management's "Polen Focus Growth Strategy" delivered a -1.37% gross return in Q4 2025, underperforming the Russell 1000 Growth Index (+1.12%) and the S&P 500 (+2.66%) due to concentrated mega-cap leadership and AI valuation concerns [1] - The fund faced market rotation and valuation pressures but maintained a disciplined investment approach, focusing on companies with durable competitive advantages and diversified earnings [1] - Despite short-term challenges, the fund has a constructive medium- to long-term outlook, anticipating broader market opportunities to support balanced returns for investors [1] Group 2 - Eli Lilly and Company (NYSE:LLY) is highlighted as a leading global pharmaceutical firm with strong growth in key therapeutic areas and robust financial results [2] - Eli Lilly's stock had a one-month return of -1.20%, trading between $623.78 and $1,133.95 over the last 52 weeks, and closed at approximately $1,039.51 per share on January 27, 2026, with a market capitalization of about $931.876 billion [2] - In Q4 2025, Eli Lilly was the top performing relative contributor to the portfolio, with a stock price rally of over 40% driven by strong financial results and an agreement with the White House to lower GLP-1 drug prices, which is expected to increase the addressable market in the U.S. [3]